ServiceNow Security Incident Response for Life Sciences and Pharma

Responding to a security event on a life sciences system means detecting it, containing it and reporting it in a way that keeps clinical, manufacturing and research records defensible. This page helps a security or quality lead decide who declares an incident on a validated system and what happens in the first hour.

High-value intellectual property and research data in pharma

Life Sciences and Pharma organisations protect intellectual property worth billions of dollars. Proprietary research data, compound formulations and development timelines represent years of investment. Security incidents that compromise this data create direct financial and competitive impact. Incident Response must prioritise detection and containment of data breaches affecting intellectual property.

Regulatory data in clinical trials is confidential and protected by law. Patient data in trials cannot be disclosed without consent. Incident Response must treat breaches involving clinical or patient data as high severity and escalate immediately to privacy and regulatory teams.

Clinical data integrity and patient safety

Attacks on clinical trial systems can compromise data integrity. If trial data is altered, the trial results may be invalid or fraudulent. Incident Response should include procedures to validate data integrity following security events affecting clinical systems.

Patient safety depends on accurate clinical data. If adverse event data is corrupted or deleted, patient safety signals may be missed. Incident Response procedures should prioritise restoration of clinical data integrity and validation of data accuracy following incidents.

Incident Response procedures must comply with regulatory requirements. Good Clinical Practice regulations mandate specific incident handling procedures and regulatory notification timelines for incidents affecting trial integrity or patient safety. Compliance teams should confirm requirements and build them into incident procedures.

Intellectual property theft and competitive impact

Espionage targeting pharmaceutical research is common. Attackers seek formulations, manufacturing processes and development timelines. Incident Response should assume that successful intrusions may have compromised intellectual property. Investigation should focus on identifying what information was accessed and assessing competitive impact.

Manufacturing process improvements and cost reductions may be stolen. If competitors gain access to optimised manufacturing processes, they can reduce costs and undercut pricing. Incident Response should assess whether manufacturing data was compromised and prioritise containment.

Supply chain information and supplier relationships may be targeted. If supplier names and contract terms are compromised, competitors could approach suppliers directly or undercut pricing. Incident Response should notify affected suppliers of security events that may have exposed supplier information.

Regulatory notification and compliance

Security incidents affecting clinical trials or patient data often trigger regulatory notification requirements. Data protection regulations may mandate notification of data breaches within specified timeframes. Incident Response procedures should include regulatory notification workflows and timelines.

Regulatory bodies may audit incident response procedures following breaches. Incident Response should maintain documentation of incident discovery, notification procedures, containment actions and remediation. This evidence supports regulatory compliance and demonstrates serious incident handling.

Supply chain security obligations may require notification of third-party breaches. If a contract manufacturer or supplier suffers a breach affecting pharma data, notification to the pharma company may be required. Incident Response should track third-party incidents and assess impact.

Supply chain resilience and manufacturing continuity

Attacks on manufacturing systems can disrupt drug production. If production control systems are compromised or ransomed, manufacturing schedules are delayed. Incident Response should prioritise rapid restoration of manufacturing systems to minimise patient impact from drug shortages.

Quality systems must function for manufacturing compliance. If quality management systems are compromised or data is corrupted, manufacturing may be halted until data integrity is restored and systems are validated. Incident Response should include procedures for rapid validation and resumption of manufacturing.

Backup and recovery procedures are critical to supply chain continuity. Manufacturing control systems should have offline backups and validated recovery procedures. Incident Response testing should include validation of recovery procedures under realistic scenarios.

Investigation and forensics for regulatory entities

Regulatory agencies may request access to incident evidence following breaches. Incident Response should preserve evidence properly so that forensic analysis can proceed if required. Chain of custody procedures should be documented for regulatory trust.

Root cause analysis is often required for regulatory reporting. Incident Response should investigate not just what happened, but why security controls failed. Vulnerabilities in development practices or security architecture should be identified and remediated.

Communication and transparency

Transparency regarding incident response builds confidence with regulators, business partners and the public. Communication to affected parties should be timely and accurate. Incident Response should include procedures for regular status updates to stakeholders.

Post-Incident Review and Continuous Improvement

After each incident is resolved, conduct a post-incident review to identify root causes and prevent recurrence. Update security policies, training, and detective controls based on lessons learned. ServiceNow tracks incident trends and supports post-incident reporting.

Deciding who declares a security incident on a validated system

A security alert on a corporate laptop and a security alert on the host that runs a validated batch record system are not the same event, even when the indicator looks identical. The difference is what the business has to do next. On the laptop the response is often containment and cleanup. On the validated host, containment can change the state of a regulated record, interrupt a run already in progress, and start a notification path that sits outside the security team. This section is for security operations leads and incident managers who must write the declaration rules for life sciences systems, and who want those rules to hold when the person on duty is not a validation specialist.

The practical starting point is a short register of regulated systems with a named owner for each one, kept in the configuration records rather than in someone’s head. For every entry, note whether the system touches manufacturing, laboratory results, clinical data or regulatory submissions, and whether it has a documented validated state. Those attributes decide which decision path an incident follows. Without them, every alert on a laboratory or plant host gets escalated to everybody, or to nobody, and both outcomes waste time. The configuration records are where that register belongs, because the classification needs to travel with the asset when it is patched, moved or retired.

A severity model that starts from the process, not only the alert

Many incident matrices grade severity by technical impact on confidentiality, integrity and availability. Life sciences teams need a second axis, which is what the affected process is doing at the moment of detection. A short outage on a document repository is a different problem from a short outage during an active fill. The table below shows how the two axes combine. It is a starting template, and the quality function should approve the wording before anyone relies on it.

The matrix exists to stop the security team from making process decisions it cannot see. A containment step that is safe for a corporate file server can destroy the only copy of an in-flight record on a validated host. The matrix moves that decision to the person who can see the process, and it makes the handover explicit so nobody assumes someone else has already checked.

A first-hour sequence for a regulated host

When a signal lands on a regulated host, the first hour is mostly about order. The sequence below works for many teams, provided each step is written into the incident task and not left in a chat channel.

1. Record the time the signal was raised and the time an analyst acknowledged it. Reviewers will ask for both, and they rarely line up unless someone wrote them down at the time.
2. Confirm from the configuration records whether the affected item is marked as regulated and which validated process it supports. If the record is missing or stale, assume the stricter classification until someone verifies it.
3. Ask the system owner what is running right now. A batch, a sample sequence, a data import or a scheduled export changes the containment decision completely.
4. Choose between isolating and observing. Write the reason in one sentence, including the observation that would make you reverse the choice.
5. Open the quality notification path in parallel with technical containment rather than after it. Quality may need to judge whether the event touches a record that has already been reviewed or released.
6. Preserve logs, snapshots and configuration state before anyone restores, patches or rebuilds. Note who took each snapshot and where it is stored, so the chain of custody can be shown later.

Where the evidence trail often breaks

Evidence gaps are a frequent weakness in regulated incidents. A common pattern is that the security team did competent work and cannot prove it. Three gaps recur. The first is a decision taken on a call or in a chat thread that never reached the incident record, so the reason for isolating a system exists only in someone’s memory. The second is containment that quietly switched off audit logging on the host, which removes the record of what happened while the host was contained. The third is a closed incident with no statement about whether the data state of the affected system was checked before it returned to use.

A simple test helps. Ask whether someone who was not on the call could reconstruct the decision, the time it was made and the evidence behind it from the record alone. If the answer is no, the incident is not finished, even if the threat has gone. That reconstruction should still be possible months later, which is why the record needs to be built for an audit reader rather than for the people who worked the incident.

When a decision moves to privacy and regulatory functions

Security operations should not decide alone whether a clinical or patient data event triggers a notification duty. That judgment belongs to the privacy office and, for trial data, to the people who own the regulatory obligations of the trial. What security operations can do is make the hand-off fast. Keep a short, agreed list of facts those functions will need: which data categories may be involved, which sites or trials are affected, whether the data was altered, copied or only viewed, and whether the system holds records from more than one jurisdiction. Build that list into the incident form so it fills in as the investigation runs, not afterwards from memory.

Measures that show the process is working

Choose measures a service owner can defend in a review, and avoid targets that push analysts to close incidents quickly. Useful categories include the share of regulated-system incidents with a documented impact decision, the gap between detection and quality notification, the number of incidents reopened because evidence was incomplete, and the number of containment actions reversed after review. A rising reopen count can mean the evidence step is being skipped, rather than that the attacks are getting worse. For how incident handling feeds the rest of the security program, the security operations and incident response work is the wider frame.

Should a security incident on a laboratory instrument always stop the instrument?

No. A forced stop can destroy a sample run and create a data gap that is harder to explain than the security event itself. The usual approach is to isolate the network path and leave local operation alone, unless the laboratory owner and the incident commander agree that the output can no longer be trusted. Write the decision down with its reason.

Who owns the incident when a vendor operates the affected system?

The organization stays accountable for regulated data even when a vendor hosts or runs the system. The incident record should name the internal owner and the vendor contact, and the contract should already say who performs forensic collection and how quickly logs are shared. Finding out what the contract says during an incident is a common and avoidable gap.

What if a suspicious change turns up during a validation exercise?

Treat it as an incident from the moment it is recognized, even if the validation team believes the change came from a faulty test script. Record what was found, stop further testing on the affected configuration, and bring in quality before any test data is discarded. Clearing test records without review can remove the very evidence needed to decide whether the event was an attack.

Can the incident record itself count as validation evidence?

It can support validation evidence but does not replace the validation file for the system. The incident record shows what happened and how it was handled. The validation file shows the controls the system is expected to have. Link the two so an inspector can move between them without help.

The triage workflow article is a useful companion to the first-hour sequence above.